Category Archives: UNHLP report

Appeal from Asian Civil Society to the DG to discuss the report of United Nations Secretary-General’s High-Level Panel on Access to Medicines (HLP) at the forthcoming EB

Dr. Margaret Chan, Director-General, World Health Organization, Switzerland Dr Poonam Khetrapal Singh, Regional Director of WHO South-East Asia Region, New Delhi Dr. Raymond Busuttil, Chairman of the Executive Board, World Health Organization   18 November 2016 Re: Appeal from Asian Civil Society to … Continue reading

Posted in R&D, Uncategorized, UNHLP report | Leave a comment

India at WTO: Takes strong stand to save generic drugs industry, calls for transparent health assessment

By Shreerupa Mitra-Jha, FirstPost | November 13, 2016 Governments engaged in bilateral and regional trade investments should ensure that these agreements do not include provisions that impinge on the right to health, and as a first step should undertake public health … Continue reading

Posted in TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized, UNHLP report, WHO | Leave a comment

The U.S. Is Standing in the Way of Cheaper Drugs for the Poor

By JASON CONE and RAYMOND C. OFFENHEISER, The New York Times|OCT. 27, 2016 Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the … Continue reading

Posted in Innovation, R&D, TPP, Uncategorized, UNHLP report, WHO | Leave a comment

India to US: Will not tighten IPR rules beyond TRIPS mandate

Commerce Minister Nirmala Sitharaman demands food safety clearance mechanism during talks with US Trade Representative Source: The Hindu BusinessLine | October 20, 2016 India and the US continued to differ on the issue of intellectual property rights (IPR) norms at … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR, Patent linkage, Sec 3 (d), TRIPS, TRIPS plus, Uncategorized, UNHLP report, USTR 301 report | Leave a comment